April was a month of two competing forces. US-Iran tensions choked crude supply through the Strait of Hormuz, hammered the rupee, and kept foreign investors in a persistent sell mode. On the other side, a strong Q4 earnings season, especially in financials, metals, and pharma, reminded the market that the domestic economy was holding up, at least for now.

Before we get into April’s markets, a quick announcement: Windmill Capital is now offering Mutual Fund smallcases, a structured alternative to the accidental portfolios most of us end up with. Check out the Windmill Wisdom section below to know more.

Markets Last Month 🗓️

1. The Recovery That Wasn’t Quite

Nifty gained 7.5% for the month. Nifty 500 was up 10.5%. Midcap 100 up 13.6%. Smallcap 100 up 18.4%. On paper, April looks like a recovery. In context, it is damage control. The Nifty is still down 8% year-to-date, and the Nifty 500 is down roughly 5%. These monthly gains sit atop severe prior losses, and the market knows it.

The one sector that did not participate was IT. Roughly flat for April, it is now down more than 20% year-to-date. TCS posted its first annual revenue decline since listing. Infosys issued weak FY27 guidance and shed nearly 7% in a single session. The sector is caught between AI-driven pricing pressure on legacy services and new revenue streams that are not yet large enough to offset the slowdown.

The VIX dropped 34% through the month but remains above six-month levels. Fear has shifted from acute to chronic. The rupee hit a record low of ₹94.89 per dollar by month-end, pushed there by crude’s resurgence. Imported inflation and pressure on the current account are live risks, not tail risks.

FPIs sold ₹60,847 crore of equities during April. DIIs held the floor. By the last week of April, they had bought shares worth ₹47,577 crore, following ₹1.43 lakh crore of investment in March. That is arguably the most important structural story of the period. The domestic investor base is now large and consistent enough to cushion sustained foreign selling. May’s single most important variable remains outside India’s control: crude oil and the Strait of Hormuz. Everything else, including earnings quality, DII support, and GDP upgrades, is intact. The geopolitical discount is the one thing the market cannot price away on its own.

2. Crude Under Pressure: Price, Physics, and Goldman’s Warning

April’s oil story was not linear. It moved in three distinct cycles of escalation and false relief, each one masking a physical reality that grew more dangerous with every passing week.

The conflict had already pushed Brent from around $75 per barrel in late February to $90–95 by the end of March. On April 2, President Trump signalled that the US was close to achieving its objectives in Iran, hinting at a resolution within weeks. Crude pulled back to $85–88. The relief lasted days. By April 4–5, US-Israeli strikes on Iran’s petrochemical hubs damaged critical infrastructure and sent Brent spiralling sharply above $100. A second round of ceasefire chatter between April 8–11 pulled prices back to $92–95. Then, by mid-April, the situation materially worsened. The US blockade of the Strait of Hormuz and the breakdown of ceasefire talks created a dual-pressure system, with Iran attacking and detaining vessels while the US imposed restrictions targeting Iranian shipping simultaneously. Brent breached $105–115 and stayed elevated in the $105–120 range through the remainder of the month.

Traffic through the strait collapsed from around 125–140 ships per day to a near-standstill. Not a full shutdown, but a severely disrupted system.

Throughout all three episodes, oil markets split into two stories. Futures traders took each ceasefire headline at face value and kept pushing prices down. The physical market, actual buyers of actual barrels loaded onto actual tankers bound for real refineries, knew oil was not moving freely and paid a steep premium above futures prices. Two markets, two completely opposite readings of the same reality.

Countries drew down emergency oil reserves at the fastest rate in nearly a decade to cover the shortfall. Goldman Sachs warned that these stockpiles are finite. When producers unable to export are eventually forced to shut down production, the process will damage the reservoir itself, with long-term consequences. When that starts happening, the futures market will no longer be able to ignore the physical reality.

3. OPEC Loses Its Second Pillar

Last week, the United Arab Emirates announced it would leave OPEC effective 1st May 2026, citing national energy strategy priorities. UAE Energy Minister Suhail Mohamed al-Mazrouei confirmed the decision followed a careful review of the country’s long-term energy goals.

The timing is not coincidental. The UAE has invested billions to reach a production capacity of 5 million barrels per day by 2027. The US-Israel-Iran conflict and the resulting blockade of the Strait of Hormuz have disrupted its ability to export. By exiting OPEC, the UAE frees itself from quota constraints entirely, gaining maximum production flexibility. It may also pursue new pipeline strategies via Fujairah, which sits on the UAE’s east coast and bypasses the current chokepoint.

The broader context matters. OPEC controlled 85% of international oil markets in the 1970s. Today it controls roughly 50%. The UAE had historically served as one of the organisation’s most important shock absorbers, with the world’s second-largest spare production capacity. Saudi Arabia remains the dominant pillar, but its ability to stabilise markets in a crisis has weakened with the UAE’s exit.

Two forces are accelerating OPEC’s declining relevance: the disruption of established trade routes and the energy transition itself. China’s massive investment in electrifying its automobile fleet is one of the clearest signals that the world is moving toward a post-oil future. That fear of growing irrelevance may have been as important to the UAE’s decision as the immediate supply disruption. With the UAE now gone, oil markets will likely see higher volatility during periods of geopolitical tension for years to come.

4. Indian Pharma’s Biggest Month in Years

April 2026 was consequential for Indian pharma across three companies, three different strategic bets, and one coherent direction.

Sun Pharma confirmed the acquisition of Organon, a US-based women’s health and biosimilars company, for $11.75 billion. This is India’s largest-ever overseas pharma deal. Organon shares surged 16% in premarket trading; Sun Pharma rose 8.5% on the announcement. The acquisition significantly expands Sun’s speciality-branded portfolio in the world’s largest drug market.

Lupin received US FDA approval for Dapagliflozin tablets, strengthening its US diabetes portfolio, and launched the drug commercially in the US shortly after. The company had won FDA approval for Sugammadex Injection the previous month, continuing a run of regulatory wins in commercially attractive categories.

Biocon launched two biosimilars in the US market: Bosaya and Aukelso. Biosimilars represent a meaningful step up the value chain. Barriers to entry are high, margins are better than generics, and the US market for biosimilars is still in early innings.

Taken together, the direction is clear. Sun Pharma is buying scale and branded presence. Lupin is building a generics pipeline in the most commercially attractive new drug category. Biocon is climbing into biosimilars, where the prize is larger and harder to replicate. Indian pharma is not just surviving the global disruption, it is using it to consolidate position.

5. Wage Hikes and the Creeping Cost Squeeze

The most consequential pressure building through April was not measured in barrels. It was measured in rupees per worker per day.

The flashpoint came from Haryana. Maruti Suzuki announced a 35% minimum wage hike to ₹165 per day, directly linked to rising living costs from the Iran conflict. Maruti shares fell 4.1% immediately. Bajaj, Ather Energy, Mahindra & Mahindra, Swaraj, and Hyundai all announced price hikes during the same period.

FMCG told a similar story. HUL, Dabur, Godrej Consumer, and Asian Paints all highlighted sustained margin pressure from crude and input cost inflation.

In chemicals, GNFC raised prices for Ethyl Acetate and Acetic Acid. Reliance Industries raised polymer prices by ₹2–5 per kg. In pharma, Chinese API prices have begun to rise amid tensions in West Asia. Paracetamol API prices have nearly doubled. Azithromycin API has surged. Some categories have seen increases of 30–40%. The stress extends beyond APIs to feedstocks: methanol, propylene, and ammonia, all critical inputs in drug manufacturing, have been disrupted by the Middle East conflict.

With retail inflation already at 3.4% in March 2026, this cost inflation is no longer a forecast. If manufacturers keep passing costs through, demand softening is the next stop.

Windmill Wisdom 🦉

Mutual Fund smallcases: Better Portfolios, Less Clutter 🆕 
Five funds, four apps, idle cash earning 3%. Most mutual fund portfolios grow by accident, not design. Windmill’s Mutual Fund smallcases give your money a structure it actually deserves. Read more →

Lupin: The Real Story Behind 10 Press Releases
Ten FDA approvals in a month sounds like noise. It isn’t. Each one is a calculated move in a larger US market strategy. Here’s what Lupin is actually building. Read more →

Polycab India: Three Problems at Once. Is It a Crisis?
A tax raid, margin pressure, and slowing revenue growth, all hitting the same quarter. Polycab’s infrastructure franchise is strong, but the turbulence is real. Here’s how to read it. Read more →

Aditya Birla Capital: A Financial Conglomerate Finding Its Stride
41% profit growth. A ₹39,618 crore investment from MUFG. Aditya Birla Capital is no longer just a holding company; it’s becoming a financial platform. Here’s what changed. Read more →

Every Car Has More Uno Minda Than You Think
Most investors know Uno Minda as an auto parts company. Few have mapped just how deeply embedded it is in every vehicle rolling off an Indian production line, and what that means as EVs scale. Read more →

Rebalance Completed 🧮

Watch out for our quant-based and AI-based model smallcases’ rebalances.

• Defence Picks – AI Model
• Growth Multicap – Quant
• Quality Bluechip – Quant
• Quality Smallcap – Quant

Head over to the smallcase app, check out the smallcase of your choice, > Go to Stocks & Weights tab and scroll down to download the Portfolio Report to view the rationale behind the rebalance.

_{Disclaimer: Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.}

_{The content in these posts/articles is for informational and educational purposes only and should not be construed as professional financial advice and nor to be construed as an offer to buy /sell or the solicitation of an offer to buy/sell any security or financial products.Users must make their own investment decisions based on their specific investment objective and financial position and using such independent advisors as they believe necessary.}

_{Windmill Capital Team: Windmill Capital Private Limited is a SEBI registered research analyst (Regn. No. INH200007645) based in Bengaluru at No 51 Le Parc Richmonde, Richmond Road, Shanthala Nagar, Bangalore, Karnataka – 560025 creating Thematic & Quantamental curated stock/ETF portfolios. Data analysis is the heart and soul behind our portfolio construction & with 50+ offerings, we have something for everyone. CIN of the company is U74999KA2020PTC132398. For more information and disclosures, visit our disclosures page here.}